Rockefeller Capital Management
OTLK icon

Rockefeller Capital Management’s Outlook Therapeutics OTLK Stock Holding History

Rockefeller Capital Management’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.94K Buy
+6,250
New +$3.88K ﹤0.01% 4022

Other funds holding OTLK

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
GWM
Gilpin Wealth Management Denver, Colorado $145M AUM

Rockefeller Capital Management's OTLK Position: Q2 2026 in Review

Rockefeller Capital Management opened a new position in Outlook Therapeutics (OTLK) in Q2 2026: 6,250 shares worth $9.94K. The stake represents ﹤0.01% of the portfolio and ranks #4022 among its holdings.

69 funds tracked by Wall St. Rank hold OTLK as of Q2 2026.

  • Rockefeller Capital Management held 6,250 shares of Outlook Therapeutics worth $9.94K as of Q2 2026.
  • Outlook Therapeutics was a new Rockefeller Capital Management position in Q2 2026.
  • Outlook Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #4022 holding.
  • 69 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.